An observational study of canagliflozin versus other antihyperglycemic agents for acute pancreatitis risk in patients with type 2 diabetes patients
Latest Information Update: 28 May 2021
At a glance
- Drugs Canagliflozin (Primary) ; Antihyperglycaemics; Dipeptidyl peptidase 4 inhibitors; Glucagon-like peptide-1 receptor antagonists; Insulin; Sulfonylureas; Thiazolidinediones
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 28 May 2021 New trial record